Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 2/20 | 0.36 |
| ▸ | NOS2 | P35228 | 3/20 | 0.32 |
| ▸ | NOS3 | P29474 | 2/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | OTC | P00480 | 1/20 | 0.31 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.30 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.30 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL23248653 | 0.97 | PRCP (0.38) | PRCPNOS2NOS3NOS1DPP7 | |
| Arginine SCHEMBL14841994 | 0.97 | PRCP (0.38) | PRCPNOS2NOS3NOS1DPP7 | |
| Arginine SCHEMBL11905093 | 0.97 | PRCP (0.38) | PRCPNOS2NOS3NOS1DPP7 | |
| Arginine SCHEMBL25171512 | 0.95 | PRCP (0.33) | PRCP | |
| Arginine SCHEMBL11905292 | 0.94 | PRCP (0.35) | PRCPNOS2NOS3NOS1DPP7 | |
| Arginine SCHEMBL2501111 | 0.94 | PRCP (0.36) | PRCPNOS2NOS3NOS1DPP7 | |
| Arginine SCHEMBL17982370 | 0.94 | PRCP (0.36) | PRCPNOS2NOS3NOS1DPP7 | |
| Arginine SCHEMBL28831176 | 0.93 | PRCP (0.32) | PRCP | |
| Arginine SCHEMBL1551248 | 0.93 | PRCP (0.35) | PRCPNOS2NOS3NOS1DPP7 | |
| Arginine SCHEMBL6369693 | 0.92 | PRCP (0.37) | PRCPNOS2NOS3NOS1DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230147962-A1 | FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | PHILOCHEM AG (CH) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230147962-A1 | FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | FAP, FIBP, FGFR1 | PRCP 92/4885NOS2 4016/4885NOS3 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.